AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Over

Wereldleider in cloudverbonden medische apparaten voor slaapapneu en ademhalingszorg, met meer dan 160 miljoen patiënten in behandeling. Op software gebaseerd digitaal gezondheidsplatform.

Aandelen vergrijzende bevolking

ResMed is een wereldwijd leider in cloud-verbonden apparaten voor slaapapneu en ademhalingszorg, behandelt meer dan 160 miljoen patiënten en profiteert van door vergrijzing aangedreven vraag naar ademhalingstherapie.

Key Financials RMD

Prijs $252.55
Wijziging (1D) +2.78%
Wijziging (30D) +4.85%
Wijziging (60D) +3.20%
Wijziging (90D) -10.25%
Wijziging (180D) +3.18%
Wijziging (1Y) +6.74%
Wijziging (5Y) +26.36%
P/E-verhouding 32.09
EPS (TTM) $7.87
52-weekse bandbreedte $199.92 — $293.81
50-daags MA $252.89
Volume 971.0K

Data updated Feb 15 · Source: Twelve Data

4.3
1 reviews
Demographic Exposure
4.8
Growth Potential
4.3
Financial Stability
4.2
Dividend Reliability
3.8
Regulatory Risk
3.2
Claude Opus 4.6
AI Review
4.3/5

ResMed is a global leader in sleep apnea and respiratory care devices, positioning it squarely as a beneficiary of aging population demographics. As the elderly population grows, demand for CPAP devices, ventilators, and connected health solutions should expand meaningfully over the coming decades.

Financially, ResMed trades at a P/E of 32x with EPS of $7.87, reflecting a premium valuation justified by its dominant market position and recurring revenue from masks and accessories. The stock sits near its 50-day moving average at ~$253, well off its 52-week high of $294, suggesting potential upside if sentiment improves.

Bull case: Massive underpenetrated sleep apnea market, strong recurring revenue model, digital health integration through myAir and AirView platforms, and demographic tailwinds from aging populations globally. Bear case: GLP-1 weight-loss drugs (Ozempic/Wegovy) could reduce sleep apnea prevalence, competitive pressure from Philips' market re-entry, and the premium valuation leaves limited margin for error. The 90-day decline of -10.25% likely reflects lingering GLP-1 concerns. Despite this overhang, ResMed's fundamentals and demographic positioning remain compelling for long-term investors.

Demographic Exposure
4.8
Growth Potential
4.3
Financial Stability
4.2
Dividend Reliability
3.8
Regulatory Risk
3.2
Feb 15, 2026
ResMed Screenshot

Added: Feb 15, 2026

resmed.com

Latest from Otrai